Human CD4+CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells

Clinical and Experimental Immunology

Volumn 177, Issue 2, 2014, Pages 531-543

  Schuler, P J ^a,c   Saze, Z ^a   Hong, C S ^a   Muller, L ^a   Gillespie, D G ^b   Cheng, D ^b   Harasymczuk, M ^a   Mandapathil, M ^a,d   Lang, S ^e   Jackson, E K ^b   Whiteside, T L ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ULM   (Germany)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Adenosine; Ectonucleotidases; Exosomes; Immune suppression

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; CD39 ANTIGEN; CD4 ANTIGEN; MESSENGER RNA; NUCLEOSIDE;

ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CANCER PATIENT; CELL SEPARATION; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; EXOSOME; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYDROLYSIS; IMMUNOSUPPRESSIVE TREATMENT; MASS SPECTROMETRY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADENOSINE; ECTONUCLEOTIDASES; EXOSOMES; HUMAN TTREG; IMMUNE SUPPRESSION; PTREG;

5'-NUCLEOTIDASE; ADENOSINE; ANTIGENS, CD; APYRASE; CELL LINE; CELL MEMBRANE; CELLS, CULTURED; EXOSOMES; GENE EXPRESSION; HUMANS; IMMUNOPHENOTYPING; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; NEOPLASMS; PHENOTYPE; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 84903936227     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12354     Document Type: Article

References (41)

1. Antonioli L, Blandizzi C, Pacher P, Hasko G. Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer 2013; 13:842-857.
2. Ghiringhelli F, Bruchard M, Chalmin F, Rebe C. Production of adenosine by ectonucleotidases: a key factor in tumor immunoescape. J Biomed Biotechnol 2012; 2012: article ID 473712, 9 pages.
3. Fredholm BB. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ 2007; 14:1315-1323.
4. Bastid J, Cottalorda-Regairaz A, Alberici G, Bonnefoy N, Eliaou JF, Bensussan A. ENTPD1/CD39 is a promising therapeutic target in oncology. Oncogene 2013; 32:1743-1751.
5. Wang L, Fan J, Thompson LF etal. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J Clin Invest 2011; 121:2371-2382.
6. Deaglio S, Dwyer KM, Gao W etal. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204:1257-1265.
7. Borsellino G, Kleinewietfeld M, Di Mitri D etal. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007; 110:1225-1232.
8. Mandapathil M, Hilldorfer B, Szczepanski MJ etal. Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem 2010; 285:7176-7186.
9. Moncrieffe H, Nistala K, Kamhieh Y etal. High expression of the ectonucleotidase CD39 on T cells from the inflamed site identifies two distinct populations, one regulatory and one memory T cell population. J Immunol 2010; 185:134-143.
10. Schuler PJ, Schilling B, Harasymczuk M etal. Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients. Eur J Immunol 2012; 42:1876-1885.
11. Dwyer KM, Hanidziar D, Putheti P etal. Expression of CD39 by human peripheral blood CD4+ CD25+ T cells denotes a regulatory memory phenotype. Am J Transplant 2010; 10:2410-2420.
12. Buckley RH. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol 2004; 22:625-655.
13. Kameoka J, Tanaka T, Nojima Y, Schlossman SF, Morimoto C. Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science 1993; 261:466-469.
14. Mandapathil M, Szczepanski M, Harasymczuk M etal. CD26 expression and adenosine deaminase activity in regulatory T cells (Treg) and CD4(+) T effector cells in patients with head and neck squamous cell carcinoma. Oncoimmunology 2012; 1:659-669.
15. Duhen T, Duhen R, Lanzavecchia A, Sallusto F, Campbell DJ. Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells. Blood 2012; 119:4430-4440.
16. Abbas AK, Benoist C, Bluestone JA etal. Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol 2013; 14:307-308.
17. Schreiber TH, Wolf D, Bodero M, Podack E. Tumor antigen specific iTreg accumulate in the tumor microenvironment and suppress therapeutic vaccination. Oncoimmunology 2012; 1:642-648.
18. Whiteside TL, Schuler P, Schilling B. Induced and natural regulatory T cells in human cancer. Expert Opin Biol Ther 2012; 12:1383-1397.
19. Bergmann C, Strauss L, Zeidler R, Lang S, Whiteside TL. Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res 2007; 67:8865-8873.
20. Mandapathil M, Szczepanski MJ, Szajnik M etal. Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J Biol Chem 2010; 285:27571-27580.
21. Pulte ED, Broekman MJ, Olson KE etal. CD39/NTPDase-1 activity and expression in normal leukocytes. Thromb Res 2007; 121:309-317.
22. Thomson LF, Ruedi JM, Glass A etal. Production and characterization of monoclonal antibodies to the glycosyl phosphatidylinositol-anchored lymphocyte differentiation antigen ecto-5′-nucleotidase (CD73). Tissue Antigens 1990; 35:9-19.
23. Saze Z, Schuler PJ, Hong CS, Cheng D, Jackson EK, Whiteside TL. Adenosine production by human B cells and B cell-mediated suppression of activated T cells. Blood 2013; 122:9-18.
24. Schuler PJ, Macatangay BJ, Saze Z etal. CD4(+)CD73(+) T cells are associated with lower T-cell activation and C reactive protein levels and are depleted in HIV-1 infection regardless of viral suppression. AIDS 2013; 27:1545-1555.
25. Clayton A, Al-Taei S, Webber J, Mason MD, Tabi Z. Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. J Immunol 2011; 187:676-683.
26. Smyth LA, Ratnasothy K, Tsang JY etal. CD73 expression on extracellular vesicles derived from CD4+ CD25+ Foxp3+ T cells contributes to their regulatory function. Eur J Immunol 2013; 43:2430-2440.
27. Zhang HG, Grizzle WE. Exosomes and cancer: a newly described pathway of immune suppression. Clin Cancer Res 2011; 17:959-964.
28. Schuler PJ, Harasymczuk M, Schilling B, Lang S, Whiteside TL. Separation of human CD4+CD39+ T cells by magnetic beads reveals two phenotypically and functionally different subsets. J Immunol Methods 2011; 369:59-68.
29. Bergmann C, Strauss L, Zeidler R, Lang S, Whiteside TL. Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment. Cancer Immunol Immunother 2007; 56:1429-1442.
30. Taylor DD, Gercel-Taylor C, Lyons KS, Stanson J, Whiteside TL. T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors. Clin Cancer Res 2003; 9:5113-5119.
31. Kim JW, Wieckowski E, Taylor DD, Reichert TE, Watkins S, Whiteside TL. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res 2005; 11:1010-1020.
32. Montecalvo A, Laregina AT, Morelli AE. Methods of analysis of dendric cell-derived exosome-shuttle micro RNA and its horizontal propagation between dendritic cells. Meth. Mol Biol 2013; 1024:19-40.
33. Szczepanski MJ, Szajnik M, Welsh A, Whiteside TL, Boyiadzis M. Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1. Haematologica 2011; 96:1302-1309.
34. Mandapathil M, Lang S, Gorelik E, Whiteside TL. Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression. J Immunol Methods 2009; 346:55-63.
35. Zarek PE, Huang CT, Lutz ER etal. A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood 2008; 111:251-259.
36. Ohta A, Kini R, Ohta A, Subramanian M, Madasu M, Sitkovsky M. The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway. Front Immunol 2012; 3:1-12.
37. Strater N. Ecto-5′-nucleotidase: structure function relationships. Purinergic Signal 2006; 2:343-350.
38. Stagg J, Divisekera U, McLaughlin N etal. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci USA 2010; 107:1547-1552.
39. Allard B, Turcotte M, Stagg J. CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth. J Biomed Biotechnol 2012; 2012: article ID 485156, 8 pages.
40. Li X, Zhou T, Zhi X, Zhao F, Yin L, Zhou P. Effect of hypoxia/reoxygenation on CD73 (ecto-5′-nucleotidase) in mouse microvessel endothelial cell lines. Microvasc Res 2006; 72:48-53.
41. Rittiner JE, Korboukh I, Hull-Ryde EA etal. AMP is an adenosine A1 receptor agonist. J Biol Chem 2012; 287:5301-5309.